Drug Profile
SP 222c
Latest Information Update: 10 Mar 2009
Price :
$50
*
At a glance
- Originator Samaritan Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Oct 2004 Samaritan formed a broad strategic collaboration agreement with Pharmaplaz
- 20 Aug 2003 SP 222c is available for licensing (http://www.samaritanpharma.com)
- 05 May 2003 Preclinical trials in Cancer in USA (unspecified route)